J.R. Marsden

Final results of the EORTC 18871/DKG 80-1 randomised phase III trial

Ulrich R. Kleeberg, Stefan Suciu, E.‐B. Bröcker et al. · European Journal of Cancer · 2003 · 240 citations

Public Health, Internal Medicine, Experimental Design +8

Adjuvant Interferon in High-Risk Melanoma: The AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research Randomized Study of Adjuvant Low-Dose Extended-Duration Interferon Alfa-2a in High-Risk Resected Malignant Melanoma

B. W. Hancock, Keith Wheatley, SyedHasan Harris et al. · Journal of Clinical Oncology · 2003 · 228 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

Eggermont Am, Stefan Suciu, Mario Santinami et al. · Research Explorer (The University of Manchester) · 2008 · 111 citations

Medicine, Oncology, Pharmacotherapy +17

Effect of oral 13-cis-retinoic acid on serum lipids

F. Lyons, M F Laker, J.R. Marsden et al. · British Journal of Dermatology · 1982 · 74 citations

Life Sciences, Dermatology, Pharmacology +14

Prospective Randomized Comparison of Dacarbazine (DTIC) Versus DTIC Plus Interferon-Alpha (IFN-α) in Metastatic Melanoma

Anna Marie P. Young, J.R. Marsden, Andrew Goodman et al. · Clinical Oncology · 2001 · 65 citations

Medicine, Clinical Sciences, Oncology +12